rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Scinai Immunotherapeutics Ltd. - American Depositary Shares

SCNI · Nasdaq

Health CareBiotechnologyNot moving yet

SCNI stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 82.4% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−9 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
18% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
8 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

23 Apr – 22 Oct
18%29%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders8+4 on the quarter
New · exited4 · 0
Reported value$41K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
CITADEL ADVISORS LLCnew · filed 14 Aug 202662,257$16K+62,257
ARMISTICE CAPITAL, LLCnew · filed 14 Aug 202635,942$9,079+35,942
XTX Topco Ltdreduced · filed 14 Aug 202616,764$4,235-7,277−30.3%
RHUMBLINE ADVISERSadded · filed 12 Aug 202613,513$3,417+11,635+619.5%
StoneX Group Inc.new · filed 12 Aug 202613,092$4,563+13,092
CAPTRUST FINANCIAL ADVISORSnew · filed 13 Aug 202612,035$3,040+12,035
UBS Group AGadded · filed 13 Aug 20263,955$1,001+3,036+330.4%
MORGAN STANLEYunchanged · filed 13 Aug 202658$1500.0%
30 Jun 2024 – 30 Jun 2026
479Jun 24Dec 24Jun 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Amir Reichman Company insiderChief Executive Officer · last 16 Jun 20260 · 0
Mark Germain Company insiderDirector · last 16 Jun 20260 · 0

Same industry

MRNA ModernaLeading+118%
ENTX Entera BioLeading+51%
XNCR XencorLeading+44%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2024 · to 31 Dec 2024-88.1%
Operating profit marginFY 2025 · to 31 Dec 2025-575%
Free cash flow marginFY 2025 · to 31 Dec 2025-462%
Return on capital employedFY 2025 · to 31 Dec 2025-75.1%
Cash conversionFY 2024 · to 31 Dec 2024-132%
Research spendFY 2025 · to 31 Dec 2025181%
Revenue growthFY 2025 · to 31 Dec 202599.2%
Share count trendFY 2025 · to 31 Dec 2025307%
Cash and equivalentsFY 2025 · to 31 Dec 2025$1.7M
Free cash flowFY 2025 · to 31 Dec 2025−$6.1M

Analyst forecasts

No analyst forecasts yet.